Biel, Switzerland, 12 September 2023 - Mimix Biotherapeutics, a cutting-edge biomedical startup company, proudly welcomes Dr. André Kobelt as the newest addition to its Board of Directors, as of September 1, 2023.
André has extensive experience in the Medical field: he established Synthes in Asia and he build up the market leader in Biomaterials, Heraeus Medical. Since 2016 André has been Managing Director of Heraeus Holding, a € 30 bn revenue company in Germany.
"We are thrilled to announce the appointment of André Kobelt to our Board of Directors," said Marc Thurner, CEO of MimiX Biotherapeutics. "André brings a wealth of knowledge and a proven track record of success in the healthcare and life sciences industry. His insight and guidance will be invaluable as we continue to drive innovation and advance our mission of revolutionizing regenerative medicine."
About Mimix Biotherapeutics
Established in 2019, the company leverages Sound Induced Morphogenesis (SIM), a proprietary technology that uses sound in conjunction with cells, stem cells, spheroids, organoids & bioactives, to create tissue relevant architectures (bio-patterns). SIM replicates natures’ design strategy by controlling shape & function, the two fundamentals in developmental biology.
Sound-induced morphogenesis is born of over a decade of intensive research and development incubated at the AO Foundation in Davos, Switzerland.
Headquartered in the Swiss Innovation Park in Biel/Bienne, MimiX is focusing its energies on clinical translation, spearheaded by its first product, FastSkin®. FastSkin®, an advanced dermal substitute designed to treat acute and chronic wounds, uses the cutting-edge biofabrication technique of sound-induced morphogenesis (SIM).
MimiX Biotherapeutics is seeking FDA approval for FastSkin®, which is set to revolutionize the industry as the world's first clinical acoustic cell patterning product. This milestone marks a turning point in regenerative medicine and underscores MimiX's commitment to improving the future of healthcare.